Iovance Biotherapeutics, Inc. (IOVA)
Stock Price:
$30.54 USD
1.47 (5.06%)
Updated Aug 3, 2020 1:10 PM EDT - Market open
Key Info
| Market Cap |
3.87B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-230.20M |
| Shares Out |
146.34M |
| EPS (ttm) |
-1.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$30.54 |
| Previous Close |
$29.07 |
| Change ($) |
1.47 |
| Change (%) |
5.06% |
| Day's Open |
29.34 |
| Day's Range |
28.86 - 30.88 |
| Day's Volume |
720,326 |
| 52-Week Range |
17.67 - 41.49 |
More Stats
| Market Cap |
3.87B |
| Enterprise Value |
3.63B |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
146.34M |
| Float |
101.92M |
| EPS (basic) |
-1.84 |
| EPS (diluted) |
-1.84 |
| FCF / Share |
-1.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
14.64M |
| Short Ratio |
6.31 |
| Short % of Float |
10.48% |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
16.74 |
| Revenue |
n/a |
| Operating Income |
-237.70M |
| Net Income |
-230.20M |
| Free Cash Flow |
-201.82M |
| Net Cash |
241.66M |
| Net Cash / Share |
1.90 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-39.63% |
| ROE |
-67.88% |
| ROIC |
-79.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
11 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$47.82*
(56.58% upside)
Low
38.0
Current: $30.54
High
65.0
Target: 47.82
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -207 | -128 | -92.88 | -53.64 | -27.86 | -12.04 | -22.64 | -8.13 | -21.22 | -0.82 |
| Net Income | -198 | -124 | -92.06 | -52.89 | -27.66 | -12.04 | -25.38 | -3.31 | -25.69 | -1.61 |
| Shares Outstanding | 124 | 97.28 | 65.24 | 55.27 | 44.41 | 24.99 | 9.76 | 0.80 | 0.76 | 0.65 |
| Earnings Per Share | -1.59 | -1.27 | -1.41 | -1.85 | -0.62 | -0.48 | -3.47 | -4.14 | -34.00 | -2.00 |
| Operating Cash Flow | -159 | -101 | -78.71 | -32.67 | -18.38 | -8.63 | -3.66 | -2.24 | -6.19 | -0.62 |
| Capital Expenditures | -6.92 | -1.20 | -1.03 | -1.52 | -1.14 | -1.59 | -0.01 | - | -0.03 | - |
| Free Cash Flow | -166 | -102 | -79.74 | -34.19 | -19.52 | -10.23 | -3.67 | -2.24 | -6.22 | -0.62 |
| Cash & Equivalents | 313 | 469 | 145 | 166 | 104 | 44.91 | 19.67 | 0.01 | 0.51 | 1.29 |
| Total Debt | 11.50 | - | - | - | - | - | - | 6.48 | 5.00 | - |
| Net Cash / Debt | 301 | 469 | 145 | 166 | 104 | 44.91 | 19.67 | -6.48 | -4.49 | 1.29 |
| Assets | 345 | 481 | 155 | 172 | 106 | 46.51 | 19.87 | 0.03 | 0.57 | 1.46 |
| Liabilities | 45.68 | 14.63 | 9.89 | 4.97 | 1.63 | 1.66 | 2.27 | 11.35 | 13.35 | 0.82 |
| Book Value | 299 | 466 | 145 | 167 | 104 | 44.85 | 17.60 | -11.32 | -12.78 | 0.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Iovance Biotherapeutics, Inc. |
| Country |
United States |
| Employees |
148 |
| CEO |
Maria Fardis |
Stock Information
| Ticker Symbol |
IOVA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IOVA |
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.